Beta

Os therapies incorporatedOSTX.US Overview

US StockHealthcare
(No presentation for OSTX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

OSTX AI Insights

OSTX Overall Performance

OSTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OSTX Recent Performance

-7.91%

Os therapies incorporated

-1.10%

Avg of Sector

-0.49%

S&P500

OSTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check OSTX's Trend

OSTX Key Information

OSTX Valuation Metrics

OSTX Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Price of OSTX

OSTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OSTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
1.66
PS Ratio (TTM)
-
PB Ratio
13.65
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
1.66
PS Ratio (TTM)
-
PB Ratio
13.65
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is OSTX's latest earnings report released?

    The most recent financial report for Os therapies incorporated (OSTX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OSTX's short-term business performance and financial health. For the latest updates on OSTX's earnings releases, visit this page regularly.

  • How much cash does OSTX have?

    At the end of the period, Os therapies incorporated (OSTX) held Total Cash and Cash Equivalents of 269.83K, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is OSTX's EPS continuing to grow?

    According to the past four quarterly reports, Os therapies incorporated (OSTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OSTX?

    Os therapies incorporated (OSTX)'s Free Cash Flow (FCF) for the period is -3.73M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 57.09% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OSTX?

    The latest valuation data shows Os therapies incorporated (OSTX) has a Price-To-Earnings (PE) ratio of -1.94 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.